We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Sage Therapeutics Inc
17 own
16 watching
Current Price
$0
$-0.42
(-0.74%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
3,378.35M
52-Week High
57.02
52-Week Low
30.665
Average Volume
0.08M
Dividend Yield
--
P/E Ratio
4.1438
Market Capitalization3,378.35M52-Week High57.0252-Week Low30.665Average Volume0.08MDividend Yield--P/E Ratio4.1438What does the Sage Therapeutics Inc do?
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The company's product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and Parkinson's diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Sage Therapeutics Inc make?
News & Events about Sage Therapeutics Inc.
Pharmaceutical Business Review
3 months ago
SAGE-718 is a first-in-class NMDA receptor positive allosteric modulator (PAM) as well as lead neuropsychiatric drug candidate. It is in development as a potential oral therapy for cognitive
The post EMA grants ODD to Sage Therapeutics SAGE-718 to treat Huntingtons disease appeared first on ...
Business Wire
4 months ago
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an...
Globe Newswire
4 months ago
Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD)Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen ...
Business Wire
5 months ago
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that Chief Executive Officer, Barry Greene, will discuss the Companys progress in developing a leading brain health pipeline at the 41st Annual J.P. Morgan...
Frequently Asked Questions
Frequently Asked Questions
What is Sage Therapeutics Inc share price today?
Can Indians buy Sage Therapeutics Inc shares?
How can I buy Sage Therapeutics Inc shares from India?
Can Fractional shares of Sage Therapeutics Inc be purchased?
What are the documents required to start investing in Sage Therapeutics Inc stocks?
What is today’s traded volume of Sage Therapeutics Inc?
What is today’s market capitalisation of Sage Therapeutics Inc?
What is the 52-Week High and Low Range of Sage Therapeutics Inc?
What percentage is Sage Therapeutics Inc down from its 52-Week High?
What percentage is Sage Therapeutics Inc up from its 52-Week Low?
Current Price
$0
$-0.42
(-0.74%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.